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Rochester, MinnesotaA growing body of evidence now supports the use of transradial percutaneous intervention (TRI) as the
preferred access site for the treatment of patients with ST-segment elevation myocardial infarction
(STEMI). Historically, TRI has been avoided in the STEMI population due to concerns over longer procedure
time, longer door-to-device time, higher crossover rates, and the experience level required with TRI
compared with transfemoral access. However, in recent years, recognition of the impact of periprocedural
bleeding on mortality in patients with acute coronary syndromes has garnered interest in the utility of TRI
as an established method to reduce bleeding. Registry data, meta-analyses, and randomized control trials
all similarly demonstrate that TRI is associated with reduced periprocedural bleeding and lower mortality
compared with transfemoral access in the STEMI population. Additional beneﬁts of TRI include enhanced
patient comfort, reduced hospital length of stay, and reduced cost. Despite the evidence, trends in use of
TRI in the United States have shown a slow adoption rate as a result of multiple barriers in clinical practice
and doubts about the mechanism and causal relationship of mortality reduction with TRI. We summarize
the current evidence and propose a call to action to foster training of TRI in cardiovascular fellowship
programs and post-fellowship courses, and for more widespread implementation of TRI in STEMI
patients. (J Am Coll Cardiol Intv 2013;6:1145–8) ª 2013 by the American College of Cardiology
Foundationlitus (1)
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dHeracPeriprocedural bleeding in patients with myo-
cardial infarction who undergo percutaneous
coronary intervention (PCI) is strongly associated
with increased mortality (2). Despite improvements
in antiplatelet agents, anticoagulation strategies,
and smaller sheath size, access-site bleeding
remains the single most common cause of peri-
procedural hemorrhage. The transradial approach is
now a well-established method to reduce peri-
procedural bleeding. Although recent data show
a trend of increasing use of transradial percutaneous
intervention (TRI) for ST-segment elevationivision of Cardiovascular Diseases, Mayo Clinic College of
Rochester, Minnesota. The authors have reported that they
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ccepted August 1, 2013.myocardial infarction (STEMI), the vast majority
of hospitals in the United States perform <1% TRI
for STEMI (3). In comparison, European rates are
vastly higher, ranging from 50% to 80% in some
countries (4,5). The reasons for this are unclear.Potential Mechanisms for
Improved Outcomes With TRI
A pooled analysis of 4 trials showed that peri-
procedural bleeding doubles the odds of mortality
in patients undergoing PCI (2). The exact mech-
anism by which bleeding leads to higher mor-
tality remains elusive but is likely multifactorial.
Bleeding often prompts discontinuation of anti-
thrombotic and antiplatelet therapy, sometimes
before surgical or other interventional procedures,
potentially increasing the risk of stent thrombosis
(6,7). Bleeding activates platelets and the clotting
cascade to achieve hemostasis, a response that may
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1146be overampliﬁed in patients with endothelial dysfunction
and acute coronary syndromes. Erythropoietin, released in
response to anemia, activates platelets and plasminogen
activator inhibitor-1, which also may promote a pro-
thrombotic state (8).
Evidence for Reduced Bleeding and
Mortality With TRI
A growing body of literature, including systematic reviews
and meta-analyses, 2 large randomized control trials, and
registry data, suggests that TRI for STEMI signiﬁcantly
reduces bleeding and mortality (Table 1) (3,9–12).
Registry data. A recent National Cardiovascular Data
Registry analysis from 2007 to 2011 showed that TRI was
associated with slightly longer median door-to-balloon times
(78 vs. 74 min; p < 0.0001), but a 38% relative reduction in
the adjusted risk of bleeding and a 24% relative reduction
in in-hospital mortality (3). Observational data from
Scotland (5) showed reduced 30-day and 1-year mortalityTable 1. Recent Studies Demons
First Author (Ref. #) Year
Mehta et al. (10) 2012
Romagnoli et al. (11) 2012
Jang et al. (9) 2012
Joyal et al. (12) 2012
Baklanov et al. (3) 2013
Values are n or odds ratios (OR) and 95%
NA ¼ not available; NNT ¼ number ne
TRI ¼ transradial percutaneous interventi
Abbreviations
and Acronyms
PCI = percutaneous coronary
intervention
RRR = relative risk reduction
STEMI = ST-segment
elevation myocardial
infarction
TF = transfemoral
TRI = transradial
percutaneous interventionwith TRI compared with the
transfemoral (TF) approach in
STEMI patients treated with
both primary PCI and rescue
PCI. Unpublished data from
the Swedish Coronary Angiog-
raphy and Angioplasty Registry
suggest a similar survival beneﬁt
with TRI for STEMI (13).
Finally, a recent retrospective
analysis of patients with STEMI
and cardiogenic shock at 2
high-volume radial PCI centersshowed that TRI was feasible in 50% of patients and was
associated with improved 1-year survival compared with the
TF approach (44% vs. 64%, p ¼ 0.004) (14). Registry data,
of course, can be limited by selection and referral biases.
Although registry data were analyzed using propensity score
matching, comparing 2 different treatment modalities using
observational evidence has inherent limitations becausetrating Reduced Bleeding and Mortality With TR
Study Type Sample Size
Multicenter RCT; STEMI subgroup 1,958
Multicenter RCT 1,001
Meta-analysis of 21 studies 8,534
Meta-analysis of 10 RCTs 3,347
Observational 90,879
conﬁdence intervals.
eded to treat; RCT ¼ randomized control trial; STEMI ¼ ST-se
on.unmeasured variables may have inﬂuenced which treatment
they received.
Meta-analyses. A meta-analysis of 8 randomized control
trials and 13 retrospective studies comparing TRI with the
TF approach in 8,534 STEMI patients showed marked
reductions in major adverse cardiac events (44% relative
risk reduction [RRR]), mortality (45% RRR), and major
bleeding (68% RRR) compared with TF (9). Another meta-
analysis of 10 randomized controlled trials (3,347 patients)
showed that TRI was associated with improved survival
and reduced vascular complications/hematoma, whereas
a nonsigniﬁcant trend toward reduced major bleeding with
TRI was found (12).
Randomized trials. The pre-speciﬁed STEMI subgroup of
the RIVAL (Radial Versus Femoral Access for Coronary
Intervention) trial showed that TRI was associated with
reduced mortality and fewer vascular and ACUITY (Acute
Catheterization and Urgent Intervention Triage Strategy)-
deﬁned bleeding (major bleeding that included large
hematomas and pseudoaneurysm) complications (10). By
contrast, among the non-ST-segment elevation myocardial
infarction (NSTEMI) subgroup, there were no signiﬁcant
differences in primary or secondary outcomes between TRI
and TF, but ACUITY-deﬁned bleeding and vascular
complications were lower. The RIFLE-STEACS (Radial
Versus Femoral Randomized Investigation in ST-Elevation
Acute Coronary Syndrome) trial randomized 1,001 STEMI
patients to TRI or TF at 4 centers in Europe (11). The
primary endpoint of 30-day net adverse cardiovascular
events occurred in 13.6% in TRI and 21.0% in TF (p ¼
0.003), with TRI being associated with lower rates of
cardiac mortality (5.2% vs. 9.2%, p ¼ 0.02) and bleeding
(7.8% vs. 12.2%, p ¼ 0.03), and shorter hospital stay (5 vs. 6
days, p ¼ 0.008). Importantly, all participating interven-
tional cardiologists in the RIFLE-STEACS study were
high-volume operators (150 PCIs/year) and had expertise
in both approaches, meeting the minimal proﬁciency
criterion of 50% TRIs per year.
Study limitations. Although the RIFLE-ACS study was
a multicenter randomized trial, it included only 4 centers,I for STEMI
Bleeding ORs
TR vs. TF
Mortality ORs
TR vs. TF
NNT to Prevent
1 Bleeding Event
NNT to Prevent
1 Death
0.49 (0.28–0.84) 0.39 (0.20–0.76) 48 52
0.64 (0.44–0.94) 0.57 (0.36–0.90) 23 25
0.32 (0.22–0.48) 0.55 (0.42–0.72) 65 53
0.63 (0.35–1.12) 0.53 (0.33–0.84) NA 61
0.62 (0.53–0.72) 0.76 (0.57–0.99) 25 207
gment elevation myocardial infarction; TF ¼ transfemoral; TR ¼ transradial;
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1147with operators required to be high volume. Use
of bivalirudin, a pharmacological intervention known to
reduce bleeding, was infrequent in both treatment groups.
Legitimate concerns over the RIVAL trial results include
the fact that the STEMI analysis was a pre-speciﬁed
subgroup. Additionally, the study was primarily powered for
combined NSTEMI and STEMI groups, in which the
primary and key secondary endpoints were similar between
the TRI and TF approaches. Finally, both the RIFLE-ACS
and RIVAL trials were underpowered for mortality, and
some remain skeptical of the large treatment effect size with
TRI, arguing that a larger trial is needed.
Considering the Tradeoffs
Minimally longer procedural times (from 2 to 4 min in
duration), longer ﬂuoroscopy duration, and higher crossover
rates have been shown with TRI (4% to 6%) versus TF PCI
(3%) for STEMI. Because experienced operators were the
majority in randomized trials, there is concern that proce-
dural delays may be longer for new radial operators con-
fronted with tortuous arm vascular anatomy and the need
to rapidly engage coronary arteries. Our own experience
suggests that the crossover delay is usually 5 min, can be
limited by the clock, and is unlikely to have any clinical
impact in the vast majority of patients. Ninety percent to
95% of patients will have successful TRI for STEMI, and
crossover rates diminish with increasing operator experience,
according to data from the REAL (REgistro regionale
AngiopLastiche dell’Emilia-Romagna) registry (15). The
available evidence points toward a survival beneﬁt with TRI,
perhaps because the incremental delay in door-to-device
time is outweighed by beneﬁt derived from reduced access
site–related bleeding. Furthermore, TRI does not preclude
placement of an intra-aortic balloon pump via the femoral
artery at any stage of the procedure and avoids the need for
bilateral femoral instrumentation in many patients. Femoral
access sites can be prepped and draped in TRI procedures as
back-up. Important additional beneﬁts from the patient’s
standpoint (i.e., the most important standpoint) of TRI
include improved procedural comfort, earlier ambulation,
and reduced length of stay (16). A recent Premier research
database analysis conﬁrmed that TRI was also associated
with reduced hospital costs and shorter length of stay
compared with TF-access PCI (17).
A Call to Action: What Are We Waiting For?
The wealth of evidence supporting widespread use of TRI
for patients with STEMI, and possibly extension to
NSTEMI, has important implications for interventional
cardiology training programs. Current and future trainees
need to be comfortable with TRI and thus will require that
their teachers are also comfortable with this approach.Although it may be difﬁcult to convince high-volume
operators who are very skilled in the TF approach to adopt
the radial approach, our own experience suggests that they
master radial skills quickly.Conclusions
Available evidence indicates that TRI is the optimal treat-
ment approach for patients presenting with STEMI due to
reduced bleeding and mortality. Accordingly, there is a clear
need for trainees and interventional cardiologists in practice
to master transradial skills in order to implement this
important treatment strategy.
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